Publications by authors named "Yakov Rotshteyn"

Claim this Profile
P
Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer.
Daniel P Petrylak, Philip Kantoff, Nicholas J Vogelzang, Anthony Mega, Mark T Fleming, Yakov Rotshteyn

Prostate· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel small-molecule inhibitors of hepatitis C virus entry block viral spread and promote viral clearance in cell culture.
Glen A Coburn, Danielle N Fisch, Sameer M Moorji, Jean-Marc de Muys, Jose D Murga, Yakov Rotshteyn

PLoS One· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Methylnaltrexone bromide: research update of pharmacokinetics following parenteral administration.
Yakov Rotshteyn, Thomas A Boyd, Chun-Su Yuan

Expert Opin Drug Metab Toxicol· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults.
Jeffrey M Jacobson, Jacob P Lalezari, Melanie A Thompson, Carl J Fichtenbaum, Michael S Saag, Yakov Rotshteyn

Antimicrob Agents Chemother· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro metabolism and identification of human enzymes involved in the metabolism of methylnaltrexone.
Zeen Tong, Appavu Chandrasekaran, Hongshan Li, Yakov Rotshteyn, John C L Erve

Drug Metab Dispos· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.
Jeffrey M Jacobson, Melanie A Thompson, Jacob P Lalezari, Michael S Saag, Barry S Zingman, Yakov Rotshteyn

J Infect Dis· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolism of intravenous methylnaltrexone in mice, rats, dogs, and humans.
Appavu Chandrasekaran, Zeen Tong, Hongshan Li, John C L Erve, William DeMaio, Yakov Rotshteyn

Drug Metab Dispos· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.
Jeffrey M Jacobson, Michael S Saag, Melanie A Thompson, Margaret A Fischl, Ralph Liporace, Yakov Rotshteyn

J Infect Dis· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.
Kenneth J Valenzano, Laykea Tafesse, Gary Lee, James E Harrison, Jamie M Boulet, Yakov Rotshteyn

Neuropharmacology· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and evaluation of pyridazinylpiperazines as vanilloid receptor 1 antagonists.
Laykea Tafesse, Qun Sun, Lori Schmid, Kenneth J Valenzano, Yakov Rotshteyn

Bioorg Med Chem Lett· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted mu opioid agonist with antihyperalgesic activity: I. In vitro pharmacological characterization and pharmacokinetic properties.
Kenneth J Valenzano, Wendy Miller, Zhengming Chen, Shen Shan, Gregg Crumley, Yakov Rotshteyn

J Pharmacol Exp Ther· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted Mu opioid agonist with antihyperalgesic activity: II. In vivo pharmacological characterization in the rat.
Garth T Whiteside, James E Harrison, Michelle S Pearson, Zhengming Chen, Marian E Fundytus, Yakov Rotshteyn

J Pharmacol Exp Ther· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
4
4-(2-pyridyl)piperazine-1-carboxamides: potent vanilloid receptor 1 antagonists.
Qun Sun, Laykea Tafesse, Khondaker Islam, Xiaoming Zhou, Sam F Victory, Yakov Rotshteyn

Bioorg Med Chem Lett· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacology of a new cyclic nucleotide phosphodiesterase type 4 inhibitor, V11294.
Donna D Gale, Peter Hofer, Domenico Spina, Esther A Seeds, Katherine H Banner, Yakov Rotshteyn

Pulm Pharmacol Ther· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties.
Kenneth J Valenzano, Elfrida R Grant, Gang Wu, Mohamed Hachicha, Lori Schmid, Yakov Rotshteyn

J Pharmacol Exp Ther· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic and pharmacodynamic profile following oral administration of the phosphodiesterase (PDE)4 inhibitor V11294A in healthy volunteers.
Donna Donigi Gale, Linda J Landells, Domenico Spina, Alan J Miller, Kate Smith, Yakov Rotshteyn

Br J Clin Pharmacol· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis